CN108430991B - Cgrp受体拮抗剂 - Google Patents

Cgrp受体拮抗剂 Download PDF

Info

Publication number
CN108430991B
CN108430991B CN201680063940.2A CN201680063940A CN108430991B CN 108430991 B CN108430991 B CN 108430991B CN 201680063940 A CN201680063940 A CN 201680063940A CN 108430991 B CN108430991 B CN 108430991B
Authority
CN
China
Prior art keywords
methyl
migraine
compound
acid
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680063940.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN108430991A (zh
Inventor
约翰·安德鲁·克里斯托弗
迈尔斯·斯图尔特·康格里夫
萨拉·乔安妮·巴克内尔
弗兰切斯卡·德弗洛里安
马克·匹克沃斯
乔纳森·斯特芬·马松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexla Pharmaceuticals Uk Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of CN108430991A publication Critical patent/CN108430991A/zh
Application granted granted Critical
Publication of CN108430991B publication Critical patent/CN108430991B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201680063940.2A 2015-10-30 2016-10-28 Cgrp受体拮抗剂 Active CN108430991B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1519194.3A GB201519194D0 (en) 2015-10-30 2015-10-30 CGRP receptor antagonists
GB1519194.3 2015-10-30
PCT/IB2016/056519 WO2017072723A1 (en) 2015-10-30 2016-10-28 Cgrp receptor antagonists

Publications (2)

Publication Number Publication Date
CN108430991A CN108430991A (zh) 2018-08-21
CN108430991B true CN108430991B (zh) 2021-01-05

Family

ID=55130446

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680063940.2A Active CN108430991B (zh) 2015-10-30 2016-10-28 Cgrp受体拮抗剂

Country Status (13)

Country Link
US (3) US9688660B2 (https=)
EP (1) EP3368526B1 (https=)
JP (1) JP6874014B2 (https=)
CN (1) CN108430991B (https=)
AR (1) AR106487A1 (https=)
AU (1) AU2016344689A1 (https=)
BR (1) BR112018008416A2 (https=)
CA (1) CA3002625A1 (https=)
GB (1) GB201519194D0 (https=)
IL (1) IL258894A (https=)
SG (1) SG11201803382XA (https=)
TW (1) TW201722936A (https=)
WO (1) WO2017072723A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
CA3164445A1 (en) * 2019-12-17 2021-06-24 Biohaven Pharmaceutical Holding Company Ltd. Intranasal pharmaceutical compositions of cgrp inhibitors
WO2024046223A1 (zh) * 2022-08-30 2024-03-07 熙源安健医药（上海）有限公司 吲唑甲酰胺类衍生物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123232A1 (en) * 2010-03-30 2011-10-06 Bristol-Myers Squibb Company Cgrp receptor antagonist

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
DE59711622D1 (de) 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
DE19952146A1 (de) * 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
BRPI0311812B8 (pt) * 2002-06-05 2021-05-25 Bristol Myers Squibb Co antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
CA2549330A1 (en) 2003-12-05 2005-07-21 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050233980A1 (en) * 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
AU2005295855B2 (en) 2004-10-14 2011-08-18 Merck Sharp & Dohme Corp. CGRP receptor antagonists
AU2005299852B2 (en) 2004-10-22 2011-08-04 Merck Sharp & Dohme Corp. CGRP receptor antagonists
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
PE20080370A1 (es) 2006-06-08 2008-06-13 Boehringer Ingelheim Int Derivados de quinazolinona como antagonistas de cgrp
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
HUE025547T2 (en) * 2008-12-19 2016-02-29 Boehringer Ingelheim Int Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123232A1 (en) * 2010-03-30 2011-10-06 Bristol-Myers Squibb Company Cgrp receptor antagonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Calcitonin gene-related peptide receptor antagonists for the treatment of migraine: a patent review;Daniel V Paone et al;《Expert Opinion on Therapeutic Patents》;20091126;第19卷(第12期);1675-1713 *
Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)-piperidine-1-carboxamide (BMS-742413): A potent human CGRP antagonist with superior safety profile for the treatment of ...;Prasad V. Chaturvedula et al;《Bioorganic & Medicinal Chemistry Letters》;20130412;第23卷;3157–3161 *

Also Published As

Publication number Publication date
TW201722936A (zh) 2017-07-01
US9688660B2 (en) 2017-06-27
BR112018008416A2 (pt) 2018-10-23
WO2017072723A1 (en) 2017-05-04
AU2016344689A1 (en) 2018-05-17
US9925178B2 (en) 2018-03-27
JP6874014B2 (ja) 2021-05-19
CA3002625A1 (en) 2017-05-04
EP3368526B1 (en) 2019-12-25
JP2018532790A (ja) 2018-11-08
US20170121311A1 (en) 2017-05-04
AR106487A1 (es) 2018-01-17
SG11201803382XA (en) 2018-05-30
US10166226B2 (en) 2019-01-01
US20180153876A1 (en) 2018-06-07
IL258894A (en) 2018-06-28
CN108430991A (zh) 2018-08-21
EP3368526A1 (en) 2018-09-05
US20170239236A1 (en) 2017-08-24
GB201519194D0 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
CN108473465B (zh) Cgrp受体拮抗剂
CN108430991B (zh) Cgrp受体拮抗剂
CN108431005B (zh) Cgrp受体拮抗剂
WO2018178938A1 (en) Cgrp receptor antagonists
HK1259591B (en) Cgrp receptor antagonists
HK1259591A1 (en) Cgrp receptor antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: Cambridge County, England

Patentee after: Nexla Pharmaceuticals UK Ltd.

Country or region after: Britain

Address before: Hertfordshire

Patentee before: HEPTARES THERAPEUTICS Ltd.

Country or region before: Britain

CP03 Change of name, title or address